Pöördumine

Ref. Ares(2022)1783564 - 10/03/2022 EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY The Director-General Brussels SANTE.DDG1.B.5/AR/am(2022)1720965 NOTE TO THE PERMANENT REPRESENTATIONS OF THE MEMBER STATES TO THE EUROPEAN UNION Dear Sir / Dear Madam, Subject: Meeting of Directors-General of Member State health ministries on the revision of pharmaceutical legislation Following the successful informal meeting of Health Ministers (EPSCO) in Grenoble on 10 February where Member States expressed a strong support for a strong European Health Union, it is crucial to ensure progress that we continue the dialogue with Member States at the level of Directors-General of national health ministries. For this reason, I would like to invite the Directors General of national health ministries to a video conference meeting on Thursday the 24th of March 2022 from 14:00 to 16:00 CET. In the meeting, I would like to engage personally in an open exchange of views with the Directors General on the revision of the pharmaceutical legislation. The revision of the pharmaceutical legislation is an ambitious project, for which the Commission intends to submit legislative proposals by the end of this year. It is a first comprehensive review after nearly 20 years in an area that affects all citizens, healthcare professionals and national health systems. Moreover, it has an important economic dimension in view of the significance of pharmaceutical research and the pharmaceutical industry for the EU. The revision aims, among others, to encourage innovation in the EU, especially for unmet medical needs and ensure access to affordable medicines for patients and health system sustainability. It is a unique opportunity to collectively improve the European system, while maintaining the core ambition of delivering safe and high-quality medicines to our patients. The discussion will focus on key policy elements with political relevance relating to the upcoming revision of the pharmaceutical legislation. A detailed agenda will follow. I kindly ask the Member State permanent representations to forward this invitation to the intended recipients so that they may reserve the space in their calendars. Finally, I kindly ask that participants confirm their attendance to [email protected] by 16 March 2022 in order to receive further updates and connection details directly. Yours faithfully, (e-signed) Sandra GALLINA Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111 E-mail : [email protected]  c.c.: Mr J-F. Ryan, Ms M. Moya Diaz, Mr A. Rys, Ms O. Solomon, Mr S. Giraud, Ms R. Ardeleanu, Ms T. Palmisano (SANTE) Electronically signed on 10/03/2022 14:23 (UTC+01) in accordance with Article 11 of Commission Decision (EU) 2021/2121 2 Saatja: Webdesktop <[email protected]> Saadetud: 11.03.2022 12:25 Adressaat: SM Info <[email protected]>; Elen Ohov <[email protected]> Koopia: <[email protected]> Teema: Webdesktop: Kiri nr 10.2-11/261 / Teatakse tervishoiuministeeriumide peadirektorite kohtumisest Tere!Edastan Komisjoni kirja. Osalejast palutakse teada anda 16.03.2022.Reg. number: 10.2-11/261Reg. kuupäev: 10.03.2022Sisu: Liikmesriikide tervishoiuministeeriumide peadirektorite kohtumine farmaatsiaalaste õigusaktide läbivaatamiseks toimub 24.03.2022Meeting of Directors-General of Member State health ministries on the revision of pharmaceutical legislation - 24.03.2022Heade soovidegaTiiu [email protected]är, EV alaline esindus EL juures Saatja: [email protected] <[email protected]> Teema: Meeting of Directors-General of Member State health ministries on the revision of pharmaceutical legislation Our reference: Ares(2022)<https://webgate.ec.testa.eu/Ares/document/show.do?documentId=080166e5e88c1445&timestamp=1646411511557>1783564 Dear colleagues, Please find attached a letter on the above mentioned subject on behalf of Ms. Sandra Gallina, Director General of DG SANTE. Kindly note that this is sent by e-mail only. Kind regards, Unit “Medicines: policy, authorisation and monitoring“ [logo-ce-horizontal-en-quadri-jpg24] European Commission DG Health and Food Safety _____________ This message represents solely the views of its author and can not be regarded as the official position of the Commission. It is intended solely for the person to whom it is addressed and may contain confidential information. If you have received this message in error, please notify me as soon as possible.